Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma

por Chen, Inna, Raymond, Victoria M., Geis, Jennifer A., Collisson, Eric A., Jensen, Benny V., Hermann, Kirstine L., Erlander, Mark G., Tempero, Margaret, Johansen, Julia S.
Publicado 2017

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3(rd) Line Cetuximab and Irinotecan

por Schou, Jakob V., Rossi, Simona, Jensen, Benny V., Nielsen, Dorte L., Pfeiffer, Per, Høgdall, Estrid, Yilmaz, Mette, Tejpar, Sabine, Delorenzi, Mauro, Kruhøffer, Mogens, Johansen, Julia S.
Publicado 2014

Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy

por Lindgaard, Sidsel C., Maag, Emil, Sztupinszki, Zsófia, Chen, Inna M., Johansen, Astrid Z., Jensen, Benny V., Bojesen, Stig E., Nielsen, Dorte L., Szallasi, Zoltan, Johansen, Julia S.
Publicado 2022

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer

por Schultz, Nicolai A., Christensen, Ib J., Werner, Jens, Giese, Nathalia, Jensen, Benny V., Larsen, Ole, Bjerregaard, Jon K., Pfeiffer, Per, Calatayud, Dan, Nielsen, Svend E., Yilmaz, Mette K., Holländer, Niels H., Wøjdemann, Morten, Bojesen, Stig E., Nielsen, Kaspar R., Johansen, Julia S.
Publicado 2013

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab

por Boisen, Mogens K., Dehlendorff, Christian, Linnemann, Dorte, Nielsen, Boye S., Larsen, Jim S., Østerlind, Kell, Nielsen, Svend E., Tarpgaard, Line S., Qvortrup, Camilla, Pfeiffer, Per, Holländer, Niels H., Keldsen, Nina, Hansen, Torben F., Jensen, Brita B., Høgdall, Estrid V. S., Jensen, Benny V., Johansen, Julia S.
Publicado 2014